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Abstract 
We analyzed the DNA methylome of ten subpopulations spanning the entire B-cell 
differentiation program by whole-genome bisulfite sequencing and high-density microarrays. 
We observed that non-CpG methylation disappeared upon B-cell commitment whereas CpG 
methylation changed extensively during B-cell maturation, showing an accumulative pattern 
and affecting around 30% of all measured CpGs. Early differentiation stages mainly displayed 
enhancer demethylation, which was associated with upregulation of key B-cell transcription 
factors and affected multiple genes involved in B-cell biology. Late differentiation stages, in 
contrast, showed extensive demethylation of heterochromatin and methylation gain of 
polycomb-repressed areas, and did not affect genes with apparent functional impact in B cells. 
This signature, which has been previously linked to aging and cancer, was particularly 
widespread in mature cells with extended life span. Comparing B-cell neoplasms with their 
normal counterparts, we identified that they frequently acquire methylation changes in 
regions undergoing dynamic methylation already during normal B-cell differentiation. 
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 The multitude of cell types and tissues of an organism can be defined by their 
particular epigenetic makeup1-2. DNA methylation is an important component of the 
epigenome which is extensively modulated during regulatory and developmental processes, 
both in the context of physiological and pathological conditions3-5. Although recent reports 
have analyzed the DNA methylation profiles of various cell types at the whole-genome scale1,6-
16, the DNA methylome of a single human cell type during its complete differentiation process 
has not been defined so far. The B-cell lineage represents a paradigmatic cellular model to 
study the dynamic epigenome during cell development and specification because major B-cell 
maturation stages have distinct phenotypic and gene expression features and can be isolated 
in sufficient numbers from hematopoietic tissues17-19. 
 B-cell lymphopoiesis is a complex and tightly coordinated process guided by a 
hierarchical expression of different stage-specific transcription factors and 
microenvironmental influences20-21. The process starts in the bone marrow, where 
hematopoietic stem cells differentiate into multipotent progenitors and common lymphoid 
progenitors, which then commit to the B-cell lineage and give rise to precursor B cells. These 
precursors gradually rearrange their immunoglobulin genes and differentiate into mature 
naive B cells, which leave the bone marrow to enter the blood stream. Resting naive B cells 
transit through lymph nodes and, eventually, they are activated by specific antigens via 
activation of the B-cell receptor, which induces the germinal center reaction. Germinal center 
B cells further rearrange and mutate their immunoglobulin genes, rapidly proliferate and 
differentiate. Finally, the germinal center reaction gives rise to plasma cells producing large 
amounts of high-affinity antibodies and memory B cells. Plasma cells exiting the lymph nodes 
migrate to the bone marrow where they can reside for extended periods of time, and long-
lived memory B cells recirculate through the blood and lymphoid organs, providing the basis 
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for enduring humoral immunity22-23. Hence, an interesting feature of the B-cell maturation 
process is that it entails a variety of cells with different functional features, proliferation 
abilities, microenvironmental influences and life spans, providing an exceptional opportunity 
to study the epigenome in the context of different biological processes, and to provide insights 
into the fields of cell differentiation, B-cell biology, cancer and aging. 
 
RESULTS 
Whole-genome DNA methylation maps of B-cell subpopulations 
 We generated unbiased DNA methylation maps of uncommitted hematopoietic 
progenitor cells (HPCs) and five B-cell lineage subpopulations, including pre-B-II cells (preB2Cs), 
naive B cells from peripheral blood (naiBCs), germinal center B cells (gcBCs), memory B cells 
from peripheral blood (memBCs) and plasma cells from bone marrow (bm-PCs), by whole-
genome bisulfite sequencing (WGBS) (Fig. 1a and Supplementary Table 1). We sequenced two 
biological replicates of each subpopulation and a total of 2,217 billion base pairs (bp) of which 
85–95% could be mapped (mean depth of 54-fold per sample) (Supplementary Table 2). On 
average, we measured methylation levels of 22.7 million CpGs per sample (ranging from 21 to 
25 million). Unsupervised principal component analysis (PCA) of CpG methylation levels 
showed that B-cell subpopulations segregate according to their developmental stage (Fig. 1b). 
Globally, B-cell differentiation is accompanied by a gradual widespread demethylation of the 
genome, which was more pronounced at late differentiation stages such as memBC and bm-PC 
(Fig. 1c-e). The global methylation status of CpGs was largely bimodal in all sorted cell 
populations and the level of partially methylated regions increased to 19–24% in advanced 
maturation stages (Fig. 1e). This result contrasts to other WGBS studies using whole tissues, in 
which the proportion of partially methylated regions is usually high24, and highlights the 
importance of using purified cell subpopulations for DNA methylation studies. 
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The results obtained by WGBS were complemented with the analysis of 3 to 9 
replicates of 10 different B-cell subpopulations by high-density DNA methylation microarrays25 
(Fig. 1a). These subpopulations included those analyzed by WGBS as well as pre-B-I cells 
(preB1Cs), immature B cells (iBC), tonsillar naive B cells (t-naiBCs) and tonsillar plasma cells (t-
PCs) (Supplementary Table 1). The biological replicates of each subpopulation analyzed by 
WGBS or microarrays showed high reproducibility (correlation coefficient > 0.95) 
(Supplementary Fig. 1), and both high-throughput techniques were further validated by 
bisulfite pyrosequencing (Supplementary Fig. 2). In line with WGBS, PCA of microarray data 
separated B-cell subpopulations mostly according to their developmental stage (Fig. 1f) and 
we observed a gradual global methylation loss throughout B-cell maturation (Fig. 1g). 
Interestingly, samples clustered into “antigen-inexperienced” and “antigen-experienced” cells 
(Supplementary Fig. 3). This finding indicates that proliferative gcBCs start a massive 
reconfiguration of the DNA methylome18-19 which continues in cell subpopulations with 
extended life span such as memBCs and bm-PCs. 
 
Demethylation of non-CpG sites upon B-cell commitment  
Cytosine methylation in mammals can occur outside CpGs, a phenomenon commonly 
observed in embryonic stem cells (ESCs) and neurons7-8,16. In our study, considering non-CpG 
sites with high-confidence methylation estimates and having ruled out suboptimal bisulfite 
conversion and sequence variants, we did observe non-CpG methylation, which was primarily 
confined to the most undifferentiated cells (i.e. HPCs) and occurred mainly in a CpApC context 
(Fig. 2a-c). Significant non-CpG methylation in HPCs was detected by WGBS at 25,763 sites in 
replicate 1 and 16,838 in replicate 2, with a mean methylation levels of 25.1% and 24.7%, 
respectively. Non-CpG methylation in HPCs frequently targeted the same sites in the two 
biological replicates, fact that was also confirmed by bisulfite pyrosequencing in independent 
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samples (Fig. 2d and Supplementary Fig. 4). Non-CpG methylation in HPCs was preferentially 
located in gene bodies (both introns and exons) and depleted in lamina-associated domains 
(Supplementary Fig. 5). Although the methylation microarrays only measured 3,091 non-CpG 
sites, we could confirm the WGBS results (Fig. 2e,f). Similarly to reports in ESCs 26, methylated 
non-CpGs were flanked by methylated CpGs. However, demethylation of non-CpGs and CpGs 
was not simultaneous. We observed a dramatic demethylation of non-CpGs upon B-cell 
commitment in preB2Cs, but 97% of these demethylated non-CpGs remained flanked by 
methylated CpGs (Supplementary Fig. 6). These data were confirmed by bisulfite 
pyrosequencing (Supplementary Fig. 4) and indicate that non-CpG methylation is passively 
erased from HPCs to preB2Cs without simultaneous demethylation of flanking CpGs (Fig. 2g). 
Although previous studies have reported that high expression of DNMT3A and DNMT3B is 
associated with non-CpG methylation26-27, we did not identify consistent differences in the 
expression levels of DNMTs between HPCs and preBCs (Supplementary Fig. 7).  
 
Identification of dynamic DNA methylation patterns 
Next, we focused our analysis on the modulation of CpG methylation throughout the 
complete B-cell maturation program. We identified dynamic methylation levels in 4.93 million 
CpGs (> 0.25 methylation change in one set of samples and > 0.1 in the other), which represent 
30.6 % of the 16.1 million CpGs with methylation estimates in all 12 samples analyzed. The cell 
subtypes showing the most pronounced methylation changes compared to the preceding 
stage were gcBCs, memBCs and bm-PCs (Fig. 3a and Supplementary Fig. 8). Interestingly, 
multiple genes directly involved in B-cell differentiation (e.g. ARID3A, BCL2, BLK, EBF1 and 
IRF4) show a complex modulation of their DNA methylation profile across the gene length, 
with different regulatory elements losing methylation at distinct maturation stages (Fig. 3b 
and Supplementary Fig. 9). In a previous study, 5.6 million dynamic CpGs were identified to be 
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differentially methylated in a wide range of human cell types and tissues1. Only one third of 
the dynamic CpGs in B-cell differentiation defined in our study overlapped with these CpGs 
(Supplementary Fig. 10). Although this result may in part be caused by differences in coverage 
and bioinformatic pipelines used in the two studies, it suggests that the majority of dynamic 
methylation in B cells may entail CpGs not previously detected to be differentially methylated 
in other cell types and tissues. 
 Similarly to WGBS, although at lower scale, microarray data revealed that 22.4% of the 
measured CpGs showed variable methylation levels during B-cell differentiation (n = 106,562, 
see online methods for details). Due to the more comprehensive set of samples, we used these 
data to define sets of CpGs sharing similar DNA methylation dynamics during B-cell 
differentiation. To that end, we based our next analysis on a linear model of B-cell maturation, 
from HPC to terminal differentiation of gcBC into t-PC and long-lived bm-PC. We defined 20 
major modules containing at least 500 CpGs that could be classified according to four general 
DNA methylation modulation patterns during differentiation: i) methylation levels decrease (9 
modules), ii) methylation levels first decrease and then increase (3 modules), iii) methylation 
levels first increase and then decrease (2 modules) and iv) methylation levels increase (6 
modules) (Supplementary Data 1). Three of these 20 modules covered 57.8% of all dynamic 
CpGs: module 8 defined by CpG demethylation starting in gcBCs and continuing in bm-PCs (n = 
34,604), module 9 showing demethylation only in bm-PCs (n = 13,044) and module 20 
characterized by hypermethylation in bm-PCs only (n = 13,949) (Fig. 3c). These data confirmed 
that DNA hypomethylation mainly occurs in the gcBCs and bm-PCs. Furthermore, it could be 
appreciated that hypermethylation is a late event, mainly occurring in bm-PCs. Overall, we 
may conclude that 84.5% of the dynamic CpGs either gain or lose methylation (DNA 
methylation modulation patterns i and iv, n = 90,070) as B-cell differentiation progresses. 
Hence, each B-cell differentiation stage has its specific DNA methylation pattern, but 
furthermore retains an epigenetic memory of the previous stages. Interestingly, although the 
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methylation levels of the 20 modules are able to separate B-cell maturation stages, we 
performed a complexity reduction step and selected 5 CpGs in genes important for B-cell 
differentiation such as BLK, SEMA4B, ARID3A, AICDA and PRDM1 whose methylation levels 
could accurately classify each maturation stage (Supplementary Fig. 11). 
 
Functional analysis of dynamically-methylated regions 
In general, CpGs losing methylation at any B-cell maturation stage were preferentially 
located in introns, intergenic regions and repetitive elements (e.g. LINEs, SINEs and LTRs), and 
were enriched for genomic areas lacking CpG islands (CGIs) (Supplementary Figs. 12 and 13). 
In contrast, CpGs gaining methylation were enriched for CGIs and promoter regions 
(Supplementary Fig. 12). Additionally, we classified differentially methylated sites using a 
categorization of the genome into different chromatin states in immortalized mature B cells28 
(Supplementary Fig. 14). Both WGBS and microarrays revealed that the majority of dynamic 
CpGs during B-cell differentiation were enriched for enhancer regions (mainly intragenic), 
polycomb-repressed regions or heterochromatin (Fig. 3d,e and Supplementary Figs. 15 and 
16). Demethylation in precursor B cells was mostly related to enhancer elements whereas that 
occurring exclusively from gcBCs onwards was preferentially located in heterochromatic 
regions. Gain of CpG methylation was a rare event in early B-cell differentiation but rather 
frequent in mature B cells, especially in bm-PCs. Such CpG hypermethylation targeted 
preferentially polycomb-repressed regions (Fig. 3d,e). 
Next, we studied the mechanisms underlying enhancer demethylation in the B-cell 
differentiation process. We identified a significant enrichment (FC > 2, P < 0.01) in transcription 
factor binding sites (TFBSs) of key B-cell transcription factors such as BCL11A, EBF1, IRF4, 
MEF2A, MEF2C, PAX5 or TCF3 (E2A) (Fig. 4a, Supplementary Fig. 17 and Supplementary Data 
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2 and 3). As B-cell commitment is associated with the expression of lineage-specific TFs20, we 
analyzed the transition from HPC to preB1C (module 1) in detail and, globally, we observed an 
inverse correlation between TF expression and the methylation levels of their binding sites 
(Fig. 4b,c). We further investigated the association between TF expression and the methylation 
status of their binding sites during the entire differentiation program, and in general, once a 
TFBS becomes demethylated at any B-cell differentiation stage, it remains unmethylated in 
subsequent stages, suggesting an epigenetic memory of TF binding24 (Supplementary Fig. 18).  
 At the functional level, genes within microarray-based methylation modules enriched 
for enhancer elements were involved in multiple immune system-related functions 
(Supplementary Fig. 19 and Supplementary Data 4). In contrast, CpGs in modules enriched for 
heterochromatin or polycomb-repressed regions, targeted genes not involved in the immune 
system but rather affected terms such as development, locomotion or behavior 
(Supplementary Fig. 19 and Supplementary Data 4). Based on this observation, we 
hypothesized that differential methylation in enhancer elements may be globally associated 
with gene expression, while that affecting inactive elements (i.e. heterochromatin or 
polycomb-repressed regions) may not. We initially explored the transcriptome of B-cell 
subpopulations and observed that they clustered separately using an unsupervised approach 
(Fig. 4d). We then calculated the number of genes differentially expressed and differentially 
methylated by comparing adjacent cell subpopulations. Globally, there was a poor association, 
and large transcriptional changes could be related to a minor modulation of the DNA 
methylome and vice versa (Fig. 4e). We further explored the association between DNA 
methylation patterns and gene expression by exploring genes with dynamic methylation in 
enhancers, heterochromatin and polycomb-repressed regions. We observed that both 
variability and mean expression levels of genes containing dynamic CpGs in enhancer elements 
were much higher in comparison with genes showing modulation of CpG methylation in non-
functional chromatin states such as heterochromatin and polycomb-repressed regions (P < 
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0.001; Fig. 4f-h). However, regardless of the DNA methylation pattern throughout B-cell 
maturation, dynamic CpGs target genes with higher expression levels and variation throughout 
the whole B-cell differentiation. Thus, these data suggest that there is no direct correlation 
between DNA methylation and gene expression, as previously shown elsewhere6,10, but rather 
that dynamic CpGs affecting functional elements target immune system-related genes whose 
expression is modulated during B-cell differentiation.  
 Next, we sought to analyze the functions of genes with dynamic enhancer methylation 
in more detail. As B-cell receptor signaling is a key element specific for B-cell differentiation, 
we studied the methylation pattern of 41 genes involved in this function. Out of those, 38 
(93%) had a total of 234 CpGs with dynamic methylation and were preferentially located in 
enhancers (Supplementary Fig. 20). Furthermore, we observed that 38% of all enhancers (P < 
0.001) belonged to a B-cell specific functional gene network29 (Supplementary Fig. 21).  
 As our study comprises cell subpopulations isolated from three different 
compartments (bone marrow, peripheral blood and tonsil), we aimed at detecting particular 
DNA methylation imprints related to these different locations but we did not identify any 
consistent pattern. However, we did observe that naiBCs isolated from different 
compartments (i.e. peripheral blood or tonsils) showed a massive modulation of their 
transcriptome while their methylomes remained virtually identical (Supplementary Figs. 22 
and 23). Based on this observation, we may hypothesize that the gene expression changes in t-
naiBCs are essential to optimize antigen recognition in the tonsil, followed by successful B-cell 
activation. However, when no antigen is found, the t-naiBCs will re-enter the blood stream. 
Hence, the t-naiBCs state has to be reversible, which may be the reason why no changes were 
observed at the level of the DNA methylome. 
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Epigenetic link among long-lived B cells, cancer and aging 
 We observed that long-lived B cells such as memBCs and bm-PCs23 show an extensive 
perturbation of their DNA methylome as compared to gcBCs (Supplementary Fig. 8). 
Remarkably, although bm-PCs and newly generated t-PCs share a similar transcriptome, they 
have different methylomes (Supplementary Fig. 22). The major DNA methylation changes in 
memBCs and bm-PCs affect presumably non-functional elements such as heterochromatin and 
polycomb-repressed regions. Thus, our findings suggest that  part of the epigenetic makeup of 
memBCs and bm-PCs is caused by an epigenetic drift associated with their long life span23. To 
determine whether such drift may be related to the expression of DNMTs, we analyzed 
DNMT1, DNMT3A and DNMT3B by qRT-PCR in sorted gcBCs, memBCs, t-PCs and bm-PCs. 
DNMT1 showed low levels in memBCs, t-PCs and bm-PCs (Supplementary Fig. 7). As these cell 
types are considered to be non-proliferative, our finding implies that demethylation occurs 
either through an active mechanism or passively if these cell types still proliferate at a low 
rate30. Gain of methylation of polycomb-repressed regions has been linked to the activity of 
DNMT3A and DNMT3B31-32. We detected that as compared to gcBCs, DNMT3A was 
upregulated in t-PCs and bm-PCs, and at a lower extent also in memBCs. Thus, these results 
may suggest that minor increases of this enzyme in the context of long-lived cells could result 
in hypermethylation of polycomb-repressed areas. To obtain further insights into the 
mechanisms of chromatin repression by hypermethylation at polycomb-repressed regions, we 
performed bisulfite sequencing of chromatin immunoprecipitated DNA (ChIP-BS) with a 
H3K27me3 antibody33-34. This experiment suggests that in memBCs, H3K27me3 and DNA 
methylation coexist both in CpG-rich and CpG-poor regions, and that the DNA methylation 
levels within nucleosomes containing H3K27me3 were lower than regions outside such 
nucleosomes (Supplementary Fig. 24).  
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 Remarkably, demethylation of heterochromatin (in part bound to the nuclear lamina) 
and hypermethylation of polycomb-repressed regions are among the most frequent epigenetic 
changes in solid and hematological tumors11,35-38. To analyze whether those CpGs showing 
differential methylation in long-lived B cells overlap with those becoming differentially 
methylated in cancer, we used methylation data from various lymphoid neoplasms including 
acute lymphoblastic leukemia39 (ALL, n = 46), chronic lymphocytic leukemia10 (CLL, n = 139), 
diffuse large B-cell lymphoma (DLBCL, n = 40) and multiple myeloma40 (MM, n = 104). We 
analyzed the methylation levels of CpGs losing methylation (modules 8 and 9) and those 
gaining methylation in memBCs and bm-PCs (modules 19 and 20). Indeed, we observed that, 
considering these CpGs, neoplastic cells show a DNA methylation profile similar to memBCs 
and bm-PCs (Fig. 5a-d and Supplementary Fig. 25).  To further evaluate the epigenetic link 
between normal B-cell differentiation and neoplastic transformation, we compared the DNA 
methylome of B-cell neoplasms with their normal cell counterparts, e.g. ALL39 vs. preBCs, 
DLBCL-GCB type vs. gcBCs, and MM40 vs. PCs (Fig. 6a and Supplementary Data 5). The results 
indicate that a large fraction of the CpGs differentially methylated in tumors  are dynamically 
methylated during normal B-cell differentiation, ranging from 53% to 82% for hypermethylated 
and from 29% to 84% for hypomethylated sites (Fig. 6b). Interestingly, we identified that 
hypomethylation in ALL was enriched in enhancers whereas hypomethylation in DLBCL and 
MM predominantly affected heterochromatin (Fig. 6c). Additionally, although ALL cells are 
arrested at the preBCs stage, they acquire hypermethylation in polycomb-repressed regions, 
which is characteristic of more mature differentiation stages (Fig. 6d). MM cells, in contrast, do 
not acquire hypermethylation of polycomb-repressed regions because their cellular origin 
already shows this feature, but, as they downregulate the B-cell program, they acquire 
hypermethylation of B cell-specific enhancers40. 
 Finally, global hypomethylation accompanied by local hypermethylation of polycomb 
targets is also a molecular hallmark of aging41-45. We analyzed DNA methylation values of CpGs 
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within modules 8, 9, 19 and 20 using data from 694 peripheral blood samples from donors 
ranging from 0 to 101 years43-44.  Indeed, we detected a significant correlation with age (P < 
0.01) following the same tendency as in long-lived cells and cancer cells, i.e. methylation of 
heterochromatin diminished with age whereas methylation of polycomb targets increased 
(Fig. 5e-f; Supplementary Fig. 25). We next compared B cells with short and long lifespan 
(naiBCs and memBCs, respectively) isolated simultaneously from individuals of different age 
and we detected that memBCs acquire hypomethylation of heterochromatin and 
hypermethylation of polycomb targets regardless of the chronological age of the donor 
(Supplementary Fig. 26). As the cellular composition of blood changes with age, our results 
imply that a relative increase of long-lived cells in older individuals may represent a 
confounding variable in age-related methylation studies46. 
 
Discussion 
 The B-cell maturation process is an orchestrated program integrating internal and 
environmental signals to finally give rise to plasma cells and memory B cells that play an 
essential role in adaptive immunity. Although previous reports have studied epigenetic 
changes in the context of B-cell differentiation, they only studied partial DNA methylomes 
either of precursor or mature B cells17-19,47. With the exception of few cell subpopulations such 
as transitional B cells, CD5+ B cells and splenic marginal zone B cells, our study comprises all 
major B-cell differentiation stages and represents the first whole-genome epigenetic 
characterization of a complete human cell lineage from progenitor to terminally-differentiated 
cells. The comprehensive nature of our study has allowed us to provide epigenetic insights into 
different scientific fields and offers a resource for researchers working in different areas of cell 
differentiation, B-cell biology and related diseases, cancer and aging, both at single gene and 
genome-wide levels.  
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 Our study points to a massive perturbation of the DNA methylome during B-cell 
differentiation, affecting 30% of all autosomal CpG sites. These changes follow an accumulative 
pattern in which each B-cell maturation stage, although characterized by a particular signature, 
keeps an epigenetic memory of past differentiation stages. In contrast to other reports in 
hematopoietic precursors48-49, we did observe non-CpG methylation in HPCs, which virtually 
disappeared upon B-cell commitment in regions lacking simultaneous CpG demethylation. 
Precursor B cells showed relatively small losses of CpG methylation, which mostly affected 
enhancers containing binding sites of B cell-specific TFs. The functional link between TF 
binding, CpG demethylation and enhancer activation has been recently analyzed during stem 
cell differentiation50-51 as well as in hematopoietic cells52-53, non-hematopoietic cells54 and 
cancer40,55.  
 Interestingly, more than half of all enhancers defined in immortalized mature B cells 
show dynamic DNA methylation throughout the B-cell differentiation process, and 38% of all 
genes with dynamically-methylated enhancers are included in a regulatory network associated 
with human B cells29. Although mainstream research on DNA methylation still remains 
centered on promoter regions, our results imply that DNA methylation changes in enhancers 
seems to be more closely related to cell specification and maturation1,9,56. However, similar to 
other recent studies6,10,57, we rarely observed a direct correlation between gene expression 
and DNA methylation, even in regulatory elements. Our study also suggests that at later stages 
of B-cell differentiation (from naiBC onwards), DNA methylation changes are more guided by 
other mechanisms than the intrinsic program of B-cell TFs. Upon antigen encounter, the 
germinal center reaction is induced and, at this stage, gcBCs start experiencing a wave of 
global demethylation, mostly affecting late-replicating regions such as heterochromatin and 
DNA repeats, and local hypermethylation of polycomb-repressed regions. This finding can be 
partially explained by the high proliferation rate, as normal proliferative tissues tend to lose 
methylation at late-replicating regions58. However, downstream B-cell subpopulations derived 
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from gcBCs, such as non-proliferative memBCs and PCs, which recirculate through the body 
and reside in bone marrow, respectively, acquire additional epigenetic changes in 
heterochromatin and polycomb-repressed regions. We postulate that these additional changes 
may be related to a potential epigenetic drift in the context of longevity that may be mediated 
by downregulation of DNMT1 and slight upregulation of DNMT3A. 
 Hypomethylation of heterochromatin and hypermethylation of polycomb-repressed 
regions have been previously described as an epigenetic hallmark of organismal aging, cellular 
senescence and cancer4,41-44,59-61. Here, we observe that this signature starts in proliferating 
gcBCs and becomes particularly enhanced in non-proliferative long-lived B cells. Based on our 
results, we hypothesize that not all the cells of the organism are subjected to epigenetic drift 
as an influence of time but only those with long life span. At last, one of the most relevant 
implications of our study is related to the field of cancer. We demonstrate that B-cell tumors 
and long-lived cells share in part similar DNA methylation signatures. Furthermore, comparing 
various B-cell tumors with their normal cellular counterparts, we observed that a large 
proportion of the differentially methylated sites overlap with those undergoing dynamic 
methylation during normal differentiation, especially with those changing in memBCs and bm-
PCs. Interestingly, similarly to preBCs, hypomethylation in ALL is enriched for enhancer 
elements whereas in line with gcBCs and bm-PCs, hypomethylation in DLBCL and MM is mostly 
enriched for heterochromatin. In general, this finding suggests that the epigenetic 
configuration of a particular maturation stage influences the DNA methylation changes 
acquired during its clonal expansion and neoplastic transformation. This novel strategy of 
analyzing the DNA methylome of B-cell tumors in the context of the entire differentiation 
program may allow us to provide new insights into the role of DNA methylation in cancer. We 
postulate that changes shared during neoplastic transformation and normal differentiation 
may represent epigenetic passengers whereas those exclusively taking place in tumor cells 
should contain epigenetic drivers with a potential functional impact in the disease.  
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FIGURE LEGENDS 
Figure 1. Analysis of the DNA methylome of different B-cell subpopulations by WGBS and 
microarrays. (a) Description of the B-cell subpopulations and techniques used in this study. (b) 
Unsupervised principal component analysis (PCA) of WGBS data of two biological replicates 
per cell subpopulation. (c) Circular representation of DNA methylation levels for HPC, preB2C, 
naiBC, gcBC, memBC and bm-PC measured by WGBS. CpG methylation levels were averaged in 
10-Mbp genomic windows and represented as histogram tracks. The heatmap indicates the 
DNA methylation change with respect to the sample in the next-innermost track. (d) Boxplot 
summarizing the distribution of DNA methylation levels per sample of the 16.1 million CpGs 
with methylation estimates in all 12 samples. (e) Global methylation status of samples 
measured by WGBS. Percentage of methylated (M, in red), partially methylated (PM, in yellow) 
and unmethylated (UM, in blue) CpGs. (f) Unsupervised PCA of microarray methylation data of 
all samples used in the study. (g) Median values of DNA methylation data measured by 
microarrays. HPC: hematopoietic progenitor cell. preB1C: pre-B-I cell. preB2C: pre-B-II cell. iBC: 
immature B cell. naiBC: naive B cell from peripheral blood. t-naiBC: naive B cell from tonsil. 
gcBC: germinal center B cell. t-PC: plasma cell from tonsil. memBC: memory B cell from 
peripheral blood. bm-PC: plasma cell from bone marrow. In panels d and e, R1 and R2 refer to 
the two biological replicates. 
 
Figure 2. Non-CpG methylation detected during B-cell differentiation. (a) Browser 
representation of non-CpG methylation, which takes place mostly in the CpApC sequence 
context (only chromosome 1 is shown). Methylation in the reverse strand is marked in blue 
whereas that in the forward strand appears in red. (b) Number of non-CpG sites with non-zero 
methylation in different B-cell subpopulations detected by WGBS. Methylated cytosines in the 
CpApC context are marked in dark red and those in other contexts in pale red. (c) Scatter plot 
showing the numbers of methylated non-CpG sites (*using only the 3,437 non-CpGs with 
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methylation estimates in all 12 samples and methylated in at least one of them) and median 
CpG methylation levels. In this analysis, 99% of the non-CpGs methylated in one HPC sample 
were also methylated in the biological replicate. (d) Validation of non-CpG methylation by 
bisulfite pyrosequencing in two independent biological replicates of each subpopulation. For 
this analysis, we used a CpApC site (chr2: 85,933,406) shown to be methylated in HPCs by 
WGBS. (e) Heatmap representation of 26 methylated non-CpGs measured by microarrays 
(mean methylation = 34.7%). (f) Percentage of methylated non-CpGs in distinct sequence 
contexts detected by microarrays. (g) Representation of CpG and non-CpG dynamics upon B-
cell commitment. CpG methylation is marked in blue and non-CpG methylation in green. 
Regions with CpG methylation loss (enhancer region, blue box) and non-CpG methylation loss 
(heterochromatin and polycomb-repressed region, green box) are not coupled. 
 
 
Figure 3. Dynamic DNA methylation during B-cell differentiation. (a) Differentially methylated 
CpGs detected by WGBS considering the two replicates per cell subpopulation (see online 
methods for an explanation of the criteria). (b) Smoothed DNA methylation data generated by 
WGBS across the promoter region and gene body of ARID3A and BLK. The DNA methylation 
pattern of these genes is widely modulated in different B-cell subpopulations, especially in 
enhancer regions. (c) Heatmap representation of 20 major modules of dynamic CpGs, divided 
in 4 different patterns, detected by microarrays. The number of CpGs within each module is 
given in brackets. (d) Chromatin state characterization of differentially methylated CpGs 
identified by WGBS. (e) Chromatin state characterization of the 20 major modules detected by 
microarrays. In panels d and e, numbers indicate the percentage of sites located in enhancers, 
polycomb-repressed regions or heterochromatin. The blue to red color scale represents log2 of 
enrichment values, with respect to the background. Green and blue bars represent 
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percentages of differentially methylated sites that reside in early- or late-replicating regions, 
respectively. RepT: replication timing. 
 
Figure 4. Association between DNA methylation and gene expression in different chromatin 
states. (a) Heatmap representing significant (P < 0.01) enrichments for transcription factor 
binding sites (TFBSs) in different methylation modules identified by arrays. Below the 
heatmap, log2 enrichment for enhancer, heterochromatin and polycomb-repressed regions in 
each differentially methylated group is represented. (b) Correlation between the expression 
levels of TFs and the mean methylation levels of their binding sites using samples with 
available expression and methylation data from the same donors. For this analysis, we 
analyzed methylation data from module 1 (demethylation upon B-cell commitment) and gene 
expression data of precursor cells. The white to brown color scale represents the odds ratio for 
TFBS enrichments. (c) Scatter plots showing the correlation of expression levels of PAX5, EBF1 
and IRF4 with the mean methylation of their binding sites in each sample (the number of TFBS 
associated with CpGs belonging to module M1 is shown below the TF name). (d) Unsupervised 
cluster analysis of gene expression data using the 687 tags (439 genes) with the highest 
variability (SD > 2) across the B-cell differentiation process. (e) Differentially expressed genes 
(upper part) and differentially methylated genes (lower part) in each comparison of adjacent 
cell subpopulations. (f-g) Mean expression levels (f) and expression variability (g) during B-cell 
differentiation of genes containing dynamic CpGs targeting enhancers, polycomb-repressed 
regions and heterochromatin. (h) Heatmaps showing DNA methylation levels (left) and gene 
expression levels (right) of representative genes with dynamic methylation in enhancers, 
heterochromatin and polycomb-repressed regions. 
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Figure 5. DNA methylation changes during B-cell differentiation in the context of cancer and 
aging. (a) Heatmap of a subset of CpGs from module M9 that lose methylation in 
heterochromatin regions. (b) Heatmap of subset of CpGs from module M20 that gain 
methylation in polycomb-repressed regions. (c-d) Scatter plots representing the mean 
methylation levels of CpGs in heterochromatin from M9 (c) and CpGs in polycomb-repressed 
regions from M20 (d) in different B-cell subsets and four types of hematological neoplasms. (e-
f) Mean methylation levels of CpGs in heterochromatin from M9 (e) and of CpGs in polycomb-
repressed regions from M20 (f) in whole blood samples isolated from donors of different age.  
ALL: acute lymphoblastic leukemia. CLL: chronic lymphocytic leukemia. DLBCL: diffuse large B-
cell lymphoma. MM: multiple myeloma. 
 
Figure 6. DNA methylation changes in various B-cell neoplasms as compared to their normal 
counterparts. (a) Differential methylation analysis was performed in three models of lymphoid 
neoplasms that arise from three distinct maturation stages of B-cell development: ALL vs. 
precursor B-cells (i.e. preB1C and preB2C), the GCB subgroup of DLBCL vs. gcBC, and MM vs. 
plasma cells (i.e. t-PC and bm-PC). (b) Barplots showing the proportion of dynamically 
methylated CpGs in B-cell differentiation that are also differentially methylated in 
hematological neoplasias as compared to their normal counterparts. (c) Percentage of 
hypermethylated (upper panels) and hypomethylated (lower panels) CpGs located in 
enhancers (left) , heterochromatin (middle) and polycomb-repressed regions (right). Pale 
orange, gray and burgundy represent fraction of CpGs that are dynamically  methylated during 
B-cell differentiation while dark shades of the same colors correspond to CpGs with stable 
methylation throughout B-cell maturation. (d) Heatmap representing differentially methylated 
CpGs in ALL as compared to precursor B cells in the context of normal B-cell differentiation. 
ALL: acute lymphoblastic leukemia. DLBCL: diffuse large B-cell lymphoma. MM: multiple 
myeloma. Bkgr: background of 450k microarray data. 
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ONLINE METHODS 
Isolation of B-cell subpopulations 
Precursor B cells were isolated from fetal bone marrow (22 week fetuses) using flow cytometry 
sorting. Early progenitors were isolated based on high levels of CD34 protein expression 
(CD34hi) and a lack of expression of the B-cell marker CD19. This population, designated as 
uncommitted hematopoietic progenitors (HPC), contains predominantly multipotent 
progenitors before lineage commitment and also common lymphoid progenitors and 
hematopoietic stem cells. B-cell-committed progenitors were isolated based on their 
expression of CD19 and CD34 (CD19+/CD34+), which were predominantly pre-B-I cells 
(preB1Cs). Two immature B-cell populations expressing CD19 and lacking CD34 were isolated 
and differentiated based on surface IgM (sIgM) expression: pre-B-II cells (preB2Cs) that express 
sIgM−/CD19+ and immature B cells that express sIgM+/CD19+ (iBCs). DNA methylation and 
gene expression data from these 4 subpopulations have been previously published17. 
Peripheral blood B-cell subpopulations, i.e. naive B cell (naiBCs) and memory B cells (memBCs) 
were obtained from buffy coats from healthy adult donors of age ranging between 28 and 66 
years. After Ficoll-Isopaque density centrifugation CD19+ B-cells were isolated by positive 
magnetic cell separation by using AutoMACS system (Milteny Biotec, Auburn, CA). CD19+ cells 
were labeled with anti-CD27, anti-IgD, anti-IgM, anti-IgG and anti-IgA for 15 min at room 
temperature in staining buffer (PBS with 0.5% BSA). naiBCs (CD19+/CD27-/IgD+) and memBCs 
(CD19+/CD27+/IgA+ or IgG+) were obtained by FACS sorting on FACSAriaII (BD Biosciences). 
Plasma cells (t-PCs), germinal centre B cells (gcBCs) and naive B cells (t-naiBCs) were separated 
from tonsils of children undergoing tonsillectomies (ranging in age between 2 and 13), 
obtained from the Clinica Universidad de Navarra (Pamplona, Spain) or Children’s Clinique La 
Sagesse (Rennes, France). Tonsils were minced extensively and after Ficoll-Isopaque density 
centrifugation, enrichment of B cells was performed with the AutoMACS system either by 
positive selection of CD19+ cells or by the B Cell Isolation Kit II (Milteny Biotec, Auburn, CA). t-
PCs (CD20med/CD38high), gcBCs (CD20high/CD38med) and t-naiBCs (CD20+/CD23+) were 
separated by FACS sorting. In part, t-naiBCs were also selected using a slightly different marker 
combination (i.e. CD19+/CD27-/IgD+ or IgD+/CD38low/CD27-). gcBCs were also selected by 
this marker combination: IgD-/CD38hi/CD10+/CXCR4+. t-naiBCs and gcBCs isolated with 
different markers identified the same cell subpopulations, as evidenced by the fact that each 
subpopulation shows homogeneous DNA methylation and transcriptional profiles 
(Supplementary Fig. 22). 
Plasma cells from bone marrow (bm-PCs) were selected from healthy donors ranging from 20 
to 30 years. After density gradient centrifugation, we performed a selective depletion of CD3+, 
CD14+ and CD15+ cells by immunomagnetic selection (Miltenyi Biotec, Germany), followed by 
flow cytometry cell sorting of CD45+/CD138+/CD38+ cells using a FACSAriaII (BD Biosciences) 
device.  
The purity of each of the isolated B-cell subpopulations exceeded 90% in all samples. DNA was 
extracted from purified samples by using a Qiagen kit (QIAamp DNA Mini Kit), following 
manufacturer’s instructions, and was quantified using a Nanodrop ND-100 spectrophotometer. 
DNA samples for WGBS, 450k array and BPS experiments were derived from individual donors 
with the exception of those from bm-PCs, which were pooled from 4 different donors. Total 
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RNA was extracted with TRIzol (Invitrogen) following the manufacturer’s recommendations. 
RNA quality was assessed with the Agilent 2100 Bioanalyzer. 
 
Whole-genome bisulfite sequencing  
We performed the WGBS on two independent sets of biological replicates from six B-cell 
differentiation stages. Briefly, genomic DNA (1–2 μg) was spiked with unmethylated λ DNA (5 
ng of λ DNA per μg of genomic DNA) (Promega). The DNA was shared by sonication to 50–500 
bp using a Covaris E220 and fragments of size 150–300 bp were selected using AMPure XP 
beads (Agencourt Bioscience Corp.). Genomic DNA libraries were constructed using the 
Illumina TruSeq Sample Preparation kit (Illumina Inc.) following the lllumina standard protocol: 
end repair was performed on the DNA fragments, an adenine was added to the 3’ extremities 
of the fragments and Illumina TruSeq adapters were ligated at each extremity. After adaptor 
ligation, the DNA was treated with sodium bisulfite using the EpiTexy Bisulfite kit (Qiagen) 
following the manufacturer’s instructions for formalin-fixed and paraffin-embedded (FFPE) 
tissue samples. Two rounds of bisulfite conversion were performed to assure a conversion rate 
of over 99%. Enrichment for adaptor-ligated DNA was carried out through 7 PCR cycles using 
the PfuTurboCx Hotstart DNA polymerase (Stratagene). Library quality was monitored using 
the Agilent 2100 BioAnalyzer (Agilent), and the concentration of viable sequencing fragments 
(molecules carrying adaptors at both extremities) estimated using quantitative PCR with the 
library quantification kit from KAPA Biosystem. Paired-end DNA sequencing (2x100bp) was 
then performed using the Illumina Hi-Seq 2000. Amounts of sequence reads and the 
proportion of aligned reads are shown in Supplementary Table 2.  
Read mapping and estimation of cytosine methylation levels 
Read mapping was carried out using the GEM aligner (v1.242)62 against a composite reference 
containing two copies of the human GRCh37 reference and two copies of the NCBI viral 
genome database (v35). For both the human and viral references, one copy had all C bases 
replaced by T and the other had all G bases replaced by A. The names of the contigs in the 
combined reference FASTA file were modified by adding #C2T or #G2A to the end of the contig 
names depending on the conversion performed. Before mapping was performed the original 
sequence of each read was stored. The first read of each pair then had all C bases replaced by 
T, and the second read had all G bases replaced by A. Read mapping with GEM was performed 
allowing up to 4 mismatches per read from the reference. After read mapping the original 
sequence of each read was restored. 
Estimation of cytosine levels was carried out on read pairs where both members of the read 
mapped to the same contig with consistent orientation, and there was no other such 
configuration at the same or less edit distance from the reference. After mapping, we restored 
the original read data in preparation for the inference of genotype and methylation status. We 
estimated genotype and DNA methylation status simultaneously using software developed at 
the Centro Nacional de Análisis Genómico, taking into account the observed bases, base 
quality scores and the strand origin of each read pair. For each genome position, we produced 
estimates of the most likely genotype and the methylation proportion (for genotypes 
containing a C on either strand). A phred scaled likelihood ratio for the confidence in the 
genotype call was estimated for the called genotype at each position. For each sample, CpG 
sites were selected where both bases were called as homozygous CC followed by GG with a 
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Phred score of at least 20, corresponding to an estimated genotype error level of <= 1%. Sites 
with >500x coverage depth were excluded to avoid centromeric/telomeric repetitive regions. A 
common set of called CpG sites for all analyzed samples was generated, and all subsequent 
analyses used this common set. 
Microarray-based DNA methylation analysis with 450k arrays 
We used the EZ DNA Methylation Kit (Zymo Research) for bisulfite conversion of 500 ng 
genomic DNA. Bisulfite-converted DNA was hybridized onto the HumanMethylation 450K 
BeadChip kit (Illumina) which covers 99% of RefSeq genes and 96% of CpG islands. The 
Infinium methylation assay was carried out as described previously25,63. Data from the 450k 
Human Methylation Array were analyzed in R using the minfi package64 (version: 1.6.0), 
available through the Bioconductor open source software. To exclude technical and biological 
biases that might produce false results in further analyses, we developed and optimized an 
analysis pipeline with several filters (i.e. CpGs with low detection p values, sex-specific and 
individual-specific methylation or overlapping with SNPs). Taking into account the different 
performance of Infinium I and Infinium II assays we used the subset-quantile within array 
normalization (SWAN)65 that corrects for the technical differences between the Infinium I and 
II assay designs and produces a smoother overall beta value distribution. 
Detection of non-CpG methylation and differential methylation analysis 
Cytosines in non-CpG context were identified as two adjacent nucleotides where the genotype 
of the first nucleotide was called with high confidence as homozygous C and the second was 
called with high confidence as a genotype not containing a G. Non-CpG cytosines were called 
methylated if they had at least two non-converted reads, at least six reads informative for 
methylation status, and a methylation probability greater than twice its standard deviation. 
The significance of the change in methylation levels between samples was assessed using the 
numbers of converted and non-converted reads in both samples with a chi square test, or 
Fisher's exact test when the chi square approximation was not appropriate. 
The difference in methylation levels between different stages of B-cell differentiation was 
calculated using 16.1 million CpGs with methylation estimates in all 12 samples analyzed by 
WGBS. The normal approximation to the binomial was used to test for significant differences 
of individual CpGs between samples. As we sequenced two biological replicates per cell 
subpopulation, we defined consistent DNA methylation changes between two differentiation 
stages if in one set of samples the methylation difference was above 0.25 and in the second 
set was at least a 0.1 difference in the same direction (hyper or hypomethylation). CpGs with 
dynamic methylation were defined as with differential methylation in comparisons of adjacent 
stages and in the comparison between HPCs and bm-PCs.  
To calculate the overlap between dynamically methylated CpGs in B cells and by Ziller et al1, 
we downloaded all the DMRs with dynamic CpGs from that study (GEO number GSE46644) and 
determined how many of the 4.93 million dynamic CpGs in B cells are located within DMRs 
identified by Ziller et al. 
We also defined CpGs that show variable methylation levels throughout B-cell development 
using 450k microarray data for HPC, preB1C, preB2C, iBC, naiBCs, t-naiBCs, gcBC, t-PC and bm-
PCs. From gcBCs on, B-cell differentiation is branched into memBCs or PCs and therefore 
memBCs were not included in this linear analysis. We performed pair-wise comparisons 
between all these subsets of B-cell differentiation. We defined as “dynamic” those CpGs that 
28 
 
presented a mean DNA methylation difference above 0.25 in at least one comparison 
(FDR<0.1, Wilcoxon test). Furthermore, we detected CpGs whose methylation shows a similar 
modulation pattern during the entire B-cell differentiation process and we group them into 
distinct modules. To allow for the identification of gradual changes (but consistent in different 
replicates) throughout the differentiation program, we applied a mean methylation difference 
between adjacent subpopulations of 0.1. The modules were grouped into four groups 
depending on their methylation tendency during differentiation (decrease, increase, decrease-
increase and increase-decrease). Differentially methylated sites between specific B-cell tumor 
entities and their normal cellular counterpart were identified by a mean DNA methylation 
difference above 0.25 and an FDR < 0.05. 
 
Bisulfite pyrosequencing studies 
Validation of DNA methylation levels generated by WGBS and 450k microarrays was validated 
by bisulfite pyrosequencing (BPS). Briefly, 500 ng of genomic DNA was bisulfite converted 
using the EpiTect 96 Bisulfite kit or the EpiTect Plus Bisulfite Conversion Kit (Qiagen) according 
to manufacturer’s instructions. PCR amplification of the bisulfite treated DNA was done using 
the specific primers for each of the selected CpGs and non-CpGs (Supplementary Table 3). 
These primers were determined with the PyroMark Assay Design software (Qiagen). BPS and 
DNA methylation data analysis were performed with the pyrosequencer PyroMark Q96 ID and 
PyroMark CpG software (Qiagen). 
 
Genomic and functional annotation of CpG sites 
Both WGBS and 450k microarray data were annotated using the UCSC Genome Browser 
database (hg19). For the location relative to a gene, we used these categories: TSS 1500 (from 
201 to 1,500 bp upstream of the transcriptional start site (TSS)), TSS 200 (from 1 to 200 bp 
upstream of the TSS), 5' UTR, first exon, exon (all exons excluding exon 1), intron, 3' UTR and 
intergenic regions. Owing to the presence of alternative transcription start sites and regions 
containing more than one gene, some of the CpGs were assigned multiple annotations. For the 
location relative to a CpG island (CGI), we used these groups: within CGI, in CGI shore (0–2 kb 
from the CGI edge), in CGI shelf (>2 kb to 4 kb from the CGI edge) and outside CGI. 
We also annotated all CpG probes using a recent categorization of chromatin and 
transcriptional states from the lymphoblastoid B cell line GM1287828 (ChromHMM track of the 
UCSC Genome Browser), which has a DNA methylome similar to memory B cells and plasma 
cells (Supplementary Fig. 14). Regions with chromatin states 1–3 (active, weak and poised 
promoter) were considered as "Promoter regions", states 4–7 (strong and weak enhancer) as 
“Enhancer regions”, state 8 as "Insulator", states 9 “Transcriptional transition”, state 10 
“Transcriptional elongation”, state 11 as "Weak transcription", state 12 as "Polycomb-
repressed regions" and state 13 as "Heterochromatin (nuclear lamina)". 
Replication timing in GM12878 data was obtained from the UW Repli-seq track of the UCSC 
Genome Browser. Replication timing values for all sites from the background was divided into 
3 bins: early-, mid- and late-replicating regions. Only early- and late-replicating regions were 
used for the analysis. 
The annotation of repeat elements was done based on the RepeatMasker Annotation, 
available at the UCSC Genome Browser. 
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B-cell network analysis 
We used the B-cell specific functional interaction network of Lefebvre et al.,29 containing 5,748 
nodes (genes) and 64,600 unique edges (interactions) based on Entrez gene identifiers. We 
selected the 5,668 dynamic enhancer genes and mapped them to Entrez gene identifiers 
resulting in 5,658 unique Entrez gene identifiers. 2,154 of these Entrez genes are contained in 
the B-cell network and 1,993 of them are directly connected in the network by 11,741 edges. 
This subnetwork of 1,993 nodes and 11,741 edges was investigated further. We identified 9 
communities in the subnetwork by using Gephi66 and Louvain’s method67.  
 
Chromatin immunoprecipitation coupled with bisulfite sequencing 
B cells were cross-linked with 1% formaldehyde during 8 min (RT) before FACS separation of 
memBCs. Chromatin preparation and ChIP were performed according to the BLUEPRINT 
Histone ChIP protocol with a anti-H3K27me3 antibody (C15410195, Diagenode). For whole-
genome bisulfite library construction and sequencing the immunoprecipitated DNA (50 ng) 
was sheared on a Covaris™ E220 in order to reach the fragment size of 50–500 bp and size 
selected 150 to 500 bp fragments using AMPure XP beads (Agencourt Bioscience Corp.). 500 
ng of unmethylated λ DNA (Promega) was treated in parallel on Covaris™ E220 and also size 
selected by AMPure XP beads to reach the same fragment sizes as the DNA sample. The 
unmethylated λ DNA was spiked into fragmented and size selected immunoprecipitated DNA 
(5 ng of λ DNA per 1 μg of DNA) and TruSeq Sample Preparation kit (Illumina Inc.) was used to 
prepare the Illumina library in order to add platform specific adaptors. After adaptor ligation 
450 ng of fragmented and size selected unmethylated λ DNA was added to the library. Two 
rounds of bisulfite conversion was performed to reach > 99% conversion following the 
manufacturer's instructions for formalin-fixed and paraffin-embedded (FFPE) tissue samples 
(EpiTect Bisulfite kit; Qiagen). Adaptor-ligated DNA was enriched through ten cycles of PCR 
using the KAPA HiFi Uracil+ polymerase (Kapa Biosystems). The library was run in a fraction of 
a lane of HiSeq2000 flow cell (to reach 35 million paired end reads) with read length of 2x100 
bp, according to standard Illumina operation procedures. Primary data analysis was carried out 
with the standard Illumina pipeline. 
The sequence reads were passed through the same read mapping and genotype/methylation 
calling pipeline as the conventional WGBS samples. In addition, the aligned reads were 
analyzed with the NucHunter package68, to provide predictions of the positions of H3K27me3-
containing nucleosomes. The average methylation of cytosines at all distances from 0-500 bp 
of each peak was calculated, taking into account the strand of the cytosine. The same analysis 
was performed on WGBS data from the same cell type (memBC), to allow comparison of the 
enriched (ChIP-BS) and non-enriched (WGBS) results. This analysis was repeated using only 
predicted nucleosome peaks that fell within predicted polycomb repressed regions from the 
Broad ChromHMM analysis of the ENCODE cell line GM12878. 
 
Gene ontology analysis 
The GOstat package69 available through Bioconductor was used to determine the enrichment 
of individual ontology terms in the different methylation modules as compared to all the genes 
analyzed in the 450k array. In Supplementary Data 4, the top 20 significant terms for each 
module (P < 0.001) are shown. 
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Analysis of transcription factor binding sites 
Transcription factor binding site (TFBS) information was obtained by ChIP-seq data in the 
ENCODE project and available at the UCSC Genome Browser. A total of 79 TFBS were used for 
the analysis. The relative enrichment of each TFBS was calculated as compared to the 
background. A fisher exact test was used and an Odds Ratio and a P value were assigned to 
each comparison. 
Gene expression analyses 
RNA samples of HPCs, preB1Cs, preB2Cs, naiBCs, t-naiBCs, gcBCs, memBCs, t-PCs and bm-PCs 
were hybridized to Affymetrix Human Genome U219 Array Plates according to Affymetrix 
standard protocols. The analysis of scanned images for each probe set of the array was 
obtained with GeneChip Operating Software (GCOS, Affymetrix). Raw CEL files were processed 
and normalized with the robust multichip average (RMA) algorithm using R statistical software 
in conjunction with the Affy library70 available through Bioconductor. The GeneChip Human 
Gene 1.0 ST Array data of progenitor B cells were downloaded through Gene Expression 
Omnibus under accession number GSE45461 and normalized using RMA (these data were only 
used for Fig. 4b,c). 
To evaluate the gene expression variability among B-cell subpopulations, we calculated the 
inter-cell subtype standard deviation per each of the Affymetrix tags. A global measure of the 
variability for a particular set of genes (within modules and chromatin states) was then 
calculated as the average of all the standard deviations. Differential expression between t-
naiBCs and naiBCs was calculated using Limma library available through Bioconductor, using 
the criteria of FC > 1 (log2) between two groups and adjusted P < 0.05. 
Reverse transcription and quantitative PCR for DNMTs expression was done as follows: cDNAs 
from 100 ng RNA samples were synthesized in 20 µl reaction mix using oligo dT primers and 
SuperScript III enzyme according to the manufacturer recommendations (Invitrogen). Primers 
for DNMTs were taken from Fang et al.71 whereas those for the housekeeping EEF2 gene are 
provided in Supplementary Table 3. PCR amplification was carried out with 1 µl of the 1:2 
diluted reverse transcription sample with Power SYBR green PCR master mix according to 
manufacturer recommendations (Applied Biosystems). PCR reactions were run in triplicates on 
a StepOne System (Applied Biosystems). 
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